B of A Securities Maintains Buy on Turnstone Biologics, Lowers Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
B of A Securities has maintained a Buy rating on Turnstone Biologics (NASDAQ:TSBX) but has lowered the price target from $12 to $10.
August 19, 2024 | 4:46 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
B of A Securities has maintained a Buy rating on Turnstone Biologics but reduced the price target from $12 to $10, indicating a slightly less optimistic outlook.
The maintenance of a Buy rating suggests continued confidence in Turnstone Biologics' potential, but the lowered price target reflects a tempered outlook, possibly due to market conditions or company performance. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100